Literature DB >> 26629277

Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID： 26629277      PMCID： PMC4665069     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  8 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.

Authors:  J Reusch; M W Stewart; C M Perkins; D T Cirkel; J Ye; C R Perry; R R Reinhardt; B W Bode
Journal:  Diabetes Obes Metab       Date:  2014-10-06       Impact factor: 6.577

Review 3.  Novel GLP-1 receptor agonists for diabetes.

Authors:  Alan J Garber
Journal:  Expert Opin Investig Drugs       Date:  2011-11-24       Impact factor: 6.206

4.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

5.  Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

Authors:  Bernard M Y Cheung; Kwok Leung Ong; Stacey S Cherny; Pak-Chung Sham; Annette W K Tso; Karen S L Lam
Journal:  Am J Med       Date:  2009-05       Impact factor: 4.965

6.  American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2013 May-Jun       Impact factor: 3.443

7.  HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

Authors:  Bo Ahrén; Susan L Johnson; Murray Stewart; Deborah T Cirkel; Fred Yang; Caroline Perry; Mark N Feinglos
Journal:  Diabetes Care       Date:  2014-06-04       Impact factor: 19.112

8.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112
  8 in total
  7 in total

1.  The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice.

Authors:  Caina Li; Shaocong Hou; Shuainan Liu; Yi Huan; Sujuan Sun; Quan Liu; Zhufang Shen
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-19       Impact factor: 2.483

Review 2.  Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.

Authors:  Seungah Lee; Dong Yun Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2017-03-31

Review 3.  Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.

Authors:  Sivanandy Palanisamy; Emily Lau Hie Yien; Ling Wen Shi; Low Yi Si; See Hui Qi; Laura Soon Cheau Ling; Teng Wai Lun; Yap Nee Chen
Journal:  Pharmacy (Basel)       Date:  2018-06-27

Review 4.  GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Authors:  Andrei C Sposito; Otávio Berwanger; Luiz Sérgio F de Carvalho; José Francisco Kerr Saraiva
Journal:  Cardiovasc Diabetol       Date:  2018-12-13       Impact factor: 9.951

Review 5.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 6.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14

Review 7.  Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics.

Authors:  Esen Sokullu; Hoda Soleymani Abyaneh; Marc A Gauthier
Journal:  Pharmaceutics       Date:  2019-05-03       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.